Major Shareholder Atlas Venture Files Intent to Sell $28M in Dyne Therapeutics Stock
DYN has more than doubled off its 52-week low of $8.06.
Summary
Atlas Venture, a significant shareholder in Dyne Therapeutics, has filed a Form 144 indicating intent to sell an additional 6,081 shares, following recent sales totaling over $27.9 million.
Key Events · Ownership and Investor Activity · DYN
-
Proposed Share Sale
Atlas Venture Fund XI, LP has filed a Form 144 indicating intent to sell 6,081 common shares of Dyne Therapeutics, with an approximate market value of $107,694.51.
-
Significant Recent Distribution
This proposed sale follows a series of dispositions by Atlas Venture entities between April 20 and May 4, 2026, totaling over $27.9 million in Dyne Therapeutics common stock.
-
Institutional Investor Reducing Stake
The cumulative sales by this major institutional shareholder represent a substantial reduction in their holdings, potentially signaling a shift in their investment outlook for the company.
Analysis · DYN · Life Sciences
This Form 144 filing by Atlas Venture, a major institutional shareholder, signals a continued distribution of its holdings in Dyne Therapeutics. The proposed sale of an additional $107,694 worth of shares comes after a series of sales by Atlas Venture entities totaling over $27.9 million in the past month. This sustained selling activity, representing nearly 1% of the company's market capitalization, could exert downward pressure on the stock price and indicates a reduction in conviction from a key early investor. Investors should monitor future filings for continued selling by this entity.
At the time of this filing, DYN was trading at $17.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.